Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.75
BMRN's Cash to Debt is ranked lower than
83% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. BMRN: 0.75 )
Ranked among companies with meaningful Cash to Debt only.
BMRN' s Cash to Debt Range Over the Past 10 Years
Min: 0.12  Med: 1.14 Max: No Debt
Current: 0.75
Equity to Asset 0.62
BMRN's Equity to Asset is ranked lower than
57% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BMRN: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
BMRN' s Equity to Asset Range Over the Past 10 Years
Min: -0.66  Med: 0.6 Max: 0.97
Current: 0.62
-0.66
0.97
F-Score: 2
Z-Score: 6.93
M-Score: -2.85
WACC vs ROIC
13.39%
-21.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -65.14
BMRN's Operating margin (%) is ranked higher than
52% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. BMRN: -65.14 )
Ranked among companies with meaningful Operating margin (%) only.
BMRN' s Operating margin (%) Range Over the Past 10 Years
Min: -65.14  Med: -12.42 Max: 13.41
Current: -65.14
-65.14
13.41
Net-margin (%) -54.53
BMRN's Net-margin (%) is ranked higher than
55% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. BMRN: -54.53 )
Ranked among companies with meaningful Net-margin (%) only.
BMRN' s Net-margin (%) Range Over the Past 10 Years
Min: -54.53  Med: -15.44 Max: 54.7
Current: -54.53
-54.53
54.7
ROE (%) -23.58
BMRN's ROE (%) is ranked higher than
58% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. BMRN: -23.58 )
Ranked among companies with meaningful ROE (%) only.
BMRN' s ROE (%) Range Over the Past 10 Years
Min: -141.46  Med: -9.05 Max: 39.6
Current: -23.58
-141.46
39.6
ROA (%) -14.95
BMRN's ROA (%) is ranked higher than
62% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. BMRN: -14.95 )
Ranked among companies with meaningful ROA (%) only.
BMRN' s ROA (%) Range Over the Past 10 Years
Min: -14.95  Med: -4.87 Max: 18.88
Current: -14.95
-14.95
18.88
ROC (Joel Greenblatt) (%) -78.52
BMRN's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. BMRN: -78.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BMRN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -78.52  Med: -13.76 Max: 31.1
Current: -78.52
-78.52
31.1
Revenue Growth (3Y)(%) 10.10
BMRN's Revenue Growth (3Y)(%) is ranked higher than
62% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. BMRN: 10.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BMRN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.4  Med: 12.6 Max: 97.3
Current: 10.1
-10.4
97.3
EBITDA Growth (3Y)(%) 3.50
BMRN's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. BMRN: 3.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BMRN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.2  Med: 24.7 Max: 519.3
Current: 3.5
-45.2
519.3
EPS Growth (3Y)(%) 4.00
BMRN's EPS Growth (3Y)(%) is ranked higher than
61% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. BMRN: 4.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BMRN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 4 Max: 36.7
Current: 4
0
36.7
» BMRN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BMRN Guru Trades in Q3 2015

Kyle Bass 129,501 sh (+1209.94%)
Paul Tudor Jones 6,208 sh (+201.07%)
Jim Simons 262,571 sh (+112.31%)
RS Investment Management 55,060 sh (+69.05%)
Frank Sands 11,395,866 sh (-1.99%)
Signature Select Canadian Fund 17,500 sh (-4.37%)
PRIMECAP Management 7,365,039 sh (-7.85%)
John Griffin 1,540,000 sh (-27.36%)
» More
Q4 2015

BMRN Guru Trades in Q4 2015

Louis Moore Bacon 122,000 sh (New)
RS Investment Management 99,240 sh (+80.24%)
Frank Sands 11,637,466 sh (+2.12%)
John Griffin 1,540,000 sh (unchged)
Kyle Bass Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 7,330,689 sh (-0.47%)
Jim Simons 193,571 sh (-26.28%)
» More
Q1 2016

BMRN Guru Trades in Q1 2016

Andreas Halvorsen 602,116 sh (New)
Spiros Segalas 781,714 sh (New)
PRIMECAP Management 7,350,369 sh (+0.27%)
Signature Select Canadian Fund Sold Out
Louis Moore Bacon Sold Out
Frank Sands 11,561,504 sh (-0.65%)
Jim Simons 132,071 sh (-31.77%)
John Griffin 1,000,000 sh (-35.06%)
RS Investment Management 21,120 sh (-78.72%)
» More
Q2 2016

BMRN Guru Trades in Q2 2016

Joel Greenblatt 3,144 sh (New)
Manning & Napier Advisors, Inc 139,920 sh (New)
Samuel Isaly 370,500 sh (New)
RS Investment Management 24,250 sh (+14.82%)
Andreas Halvorsen Sold Out
Jim Simons Sold Out
PRIMECAP Management 7,319,319 sh (-0.42%)
Frank Sands 10,918,317 sh (-5.56%)
John Griffin 800,000 sh (-20.00%)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:UCBJY, OTCPK:GIKLY, NAS:INCY, OTCPK:NVZMY, OTCPK:ALIOY, NAS:MDVN, OTCPK:GMXAY, NAS:JAZZ, NAS:ALKS, NAS:SGEN, NAS:ALNY, NAS:VRTX, NAS:UTHR, NAS:TSRO, NAS:ANAC, NAS:ICPT, NAS:IONS, NAS:TECH, NAS:ACAD, NAS:JUNO » details
Traded in other countries:BM8.Germany,
Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse.

Biomarin Pharmaceutical Inc was incorporated in Delaware on October 1996 and began operations on March 21, 1997. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of five approved products and multiple investigational product candidates. Approved products include VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The Company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including PEG PAL, an enzyme substitution therapy for the treatment of PKU; BMN 701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder; BMN 673, an orally available poly-ADP ribose polymerase inhibitor for the treatment of patients with certain cancers BMN 111, a peptide therapeutic for the treatment of achondroplasia, the cause of dwarfism: and BMN 190 for the treatment of late infantile neuronal ceroid lipofuscinosis(CLN2), lysomal storage disorder affecting the brain. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to federal, state, local and foreign regulation.

Top Ranked Articles about Biomarin Pharmaceutical Inc

Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Investor reports latest quarterly portfolio
Samuel Isaly (Trades, Portfolio), manager of the Eaton Vance Worldwide Health Care Fund (ETHSX), invested in three health care companies and eliminated his position in three others during the second quarter of 2016. An active health care investor, Isaly seeks long-term capital growth in health care companies that have potential for high growth and increased market share. The portfolio manager generally has 80% of his assets in health sciences industries, including biotechnology, pharmaceuticals and medical equipment. Read more...

Ratios

vs
industry
vs
history
P/B 8.09
BMRN's P/B is ranked lower than
77% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. BMRN: 8.09 )
Ranked among companies with meaningful P/B only.
BMRN' s P/B Range Over the Past 10 Years
Min: 3.68  Med: 6.85 Max: 27.45
Current: 8.09
3.68
27.45
P/S 15.76
BMRN's P/S is ranked lower than
57% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. BMRN: 15.76 )
Ranked among companies with meaningful P/S only.
BMRN' s P/S Range Over the Past 10 Years
Min: 3.39  Med: 14.97 Max: 34.36
Current: 15.76
3.39
34.36
Current Ratio 3.03
BMRN's Current Ratio is ranked lower than
63% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. BMRN: 3.03 )
Ranked among companies with meaningful Current Ratio only.
BMRN' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 6.32 Max: 18.94
Current: 3.03
0.9
18.94
Quick Ratio 2.14
BMRN's Quick Ratio is ranked lower than
69% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. BMRN: 2.14 )
Ranked among companies with meaningful Quick Ratio only.
BMRN' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 5.27 Max: 18.77
Current: 2.14
0.82
18.77
Days Inventory 585.02
BMRN's Days Inventory is ranked lower than
96% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.14 vs. BMRN: 585.02 )
Ranked among companies with meaningful Days Inventory only.
BMRN' s Days Inventory Range Over the Past 10 Years
Min: 367.05  Med: 530.66 Max: 751.15
Current: 585.02
367.05
751.15
Days Sales Outstanding 80.28
BMRN's Days Sales Outstanding is ranked lower than
62% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. BMRN: 80.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMRN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.96  Med: 74.4 Max: 86.7
Current: 80.28
50.96
86.7

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.70
BMRN's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. BMRN: -8.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMRN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.6  Med: -9.1 Max: -3.2
Current: -8.7
-32.6
-3.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.49
BMRN's Price/Tangible Book is ranked lower than
81% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. BMRN: 13.49 )
Ranked among companies with meaningful Price/Tangible Book only.
BMRN' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.13  Med: 7.54 Max: 116.7
Current: 13.49
2.13
116.7
Price/Median PS Value 1.05
BMRN's Price/Median PS Value is ranked lower than
54% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. BMRN: 1.05 )
Ranked among companies with meaningful Price/Median PS Value only.
BMRN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 1.22 Max: 9.97
Current: 1.05
0.27
9.97
Earnings Yield (Greenblatt) (%) -4.07
BMRN's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. BMRN: -4.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BMRN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.2  Med: 1.2 Max: 4
Current: -4.07
-4.2
4

More Statistics

Revenue (TTM) (Mil) $973.7
EPS (TTM) $ -3.30
Beta1.65
Short Percentage of Float4.28%
52-Week Range $62.12 - 136.85
Shares Outstanding (Mil)163.47

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 1,109 1,382 1,455
EPS ($) -2.54 -0.15 0.52
EPS w/o NRI ($) -2.54 -0.15 0.52
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for BMRN

Headlines

Articles On GuruFocus.com
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 
Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
Spiros Segalas Buys McDonald's, Microsoft, Alibaba May 05 2016 
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 

More From Other Websites
[$$] Smaller Biotech Buyout Targets After Medivation Aug 24 2016
Forbes Ranks BioMarin 10th Most Innovative Company in the World Aug 24 2016
4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss Aug 23 2016
The $150 million winner — and the losers — in Pfizer's $14 billion takeout of Medivation Aug 22 2016
Biotech's next big deal? Aug 22 2016
Betting on BioMarin Aug 22 2016
Biotechs Rise on Bet Medivation Losers Will Look to Next Deal Aug 22 2016
BioMarin (BMRN) Stock Surges on Takeover Speculation Aug 22 2016
Break Up Gilead Sciences? Not So Fast Aug 19 2016
Why You Shouldn't Bet Against BioMarin Pharmaceutical (BMRN) Stock Aug 16 2016
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen Aug 12 2016
How to Play a Nasdaq Breakout Aug 12 2016
Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat Aug 11 2016
BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Aug 11 2016
BIOMARIN PHARMACEUTICAL INC Financials Aug 11 2016
ETF’s with exposure to BioMarin Pharmaceutical, Inc. : August 9, 2016 Aug 09 2016
BioMarin Announces Pricing of Public Offering of Common Stock Aug 09 2016
BioMarin Announces Pricing of Public Offering of Common Stock Aug 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)